Milestone in Diabetes Care: FDA Clears Kirsty as Interchangeable Biosimilar to Novolog

The U.S. Food and Drug Administration (FDA) has officially approved Kirsty (insulin aspart-xjhz), marking it as the first rapid-acting interchangeable biosimilar to Novolog (insulin aspart). Kirsty will be available in two forms: a 3 mL prefilled pen for single-patient use and a 10 mL multiple-dose vial.

Designed to help manage blood sugar levels in adults and children with diabetes, Kirsty is a human insulin analog that works similarly to Novolog. As an interchangeable biosimilar, it may be substituted for Novolog at the pharmacy level, depending on individual state laws—without requiring a new prescription.

What Makes Kirsty a Biosimilar?

Biosimilars are biological products that are highly similar to already approved biologics, with no significant clinical differences in terms of safety or effectiveness. Kirsty’s approval as an interchangeable product reflects its equivalence to Novolog, ensuring reliable and consistent treatment for patients.

How It Is Used

Prefilled Pen (3 mL): For subcutaneous injection.
Vial (10 mL): Can be used subcutaneously, through an insulin pump, or intravenously.

Dosing should be customized based on patient needs, and Kirsty should not be used during low blood sugar episodes or in those with allergies to insulin aspart.

Possible Risks and Side Effects

Kirsty may cause:

Low blood sugar (hypoglycemia)
Allergic reactions (including severe cases)
Low potassium levels (hypokalemia)

Other possible side effects may include:

Injection site issues (rash, itching, redness, or pain)
Weight gain
Fat tissue changes at injection sites (lipodystrophy)

A Milestone for Diabetes Treatment

Kirsty becomes the 72nd biosimilar approved by the FDA and the fourth biosimilar insulin available in the U.S. This step is a major boost for efforts aimed at increasing access to more affordable insulin therapies without compromising quality.